2023
- · AugustOriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
- · MayOri-C101 Clinical Study Begins Enrolling Subjects with Hepatocellular Carcinoma
- · FebruaryClosed $45M Series B1 Financing Round Led by RTW and Qatar Investment Authority
- · JanuaryOriCAR-017 follow-up data published in The Lancet Haematology
2022
- · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
- · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress
Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List - · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022
- · MarchAnnounced the appointment of Dr. Weidong Cui as Chief Technology Officer
2021
- · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
- · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
- · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."
2019
- · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners
- · NovemberBecame a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center
Became one of the funded key technology start-up enterprises in Pudong New Area - · AprilOriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
2017
- · JulyOriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units
- · MayShanghai Long March Hospital (LMH) and Primary Medicine officially launched the "LMH-Primary Energy Cell Clinical Research Center" in Shanghai Long March Hospital (LMH).
2015
- · FebruaryOriCell Medical was founded by OriginCell Group; Co-founder Dr. He Xiaowen serving as the chief scientist
2022
- · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
- · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
- · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
- · AugustRaises Over $120 Million in Series B Financing
2021
- · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
- · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting
- · SeptemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting
Oricell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
2020
- · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets
Established the Shanghai Academician (Expert) Workstation< - · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
- · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
- · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD
2018
- · NovemberRecognized as a High and New Technology Enterprise
Received funding from the 2018 Pudong New Area Science and Technology Development FundThe Secretary-General of the Nobel Prize Committee visited OriCell Medical - · OctoberAttended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields
- · JuneResearch results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell
- · MaySigned a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.
- · MarchThe Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"
2016
- · MayEstablished the CAR-T technology platform with high memory and high vitality
- · FebruaryExpanded R&D team
2023
- · AugustOriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact
- · MayOri-C101 Clinical Study Begins Enrolling Subjects with Hepatocellular Carcinoma
- · FebruaryClosed $45M Series B1 Financing Round Led by RTW and Qatar Investment Authority
- · JanuaryOriCAR-017 follow-up data published in The Lancet Haematology
2022
- · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
- · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress<br>Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List
- · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022
- · MarchAnnounced the appointment of Dr. Weidong Cui as Chief Technology Officer
2021
- · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
- · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
- · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."
2019
- · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners
- · NovemberBecame a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center<br>Became one of the funded key technology start-up enterprises in Pudong New Area
- · AprilOriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
2017
- · JulyOriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units
- · MayShanghai Long March Hospital (LMH) and Primary Medicine officially launched the "LMH-Primary Energy Cell Clinical Research Center" in Shanghai Long March Hospital (LMH).
2015
- · FebruaryOriCell Medical was founded by OriginCell Group; Co-founder Dr. He Xiaowen serving as the chief scientist
2022
- · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
- · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
- · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
- · AugustRaises Over $120 Million in Series B Financing
2021
- · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
- · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting
- · SeptemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting<br>Oricell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
2020
- · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets<br>Established the Shanghai Academician (Expert) Workstation<
- · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
- · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
- · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality<br>Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD
2018
- · NovemberRecognized as a High and New Technology Enterprise<br>Received funding from the 2018 Pudong New Area Science and Technology Development FundThe Secretary-General of the Nobel Prize Committee visited OriCell Medical
- · OctoberAttended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields
- · JuneResearch results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell
- · MaySigned a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.
- · MarchThe Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"
2016
- · MayEstablished the CAR-T technology platform with high memory and high vitality
- · FebruaryExpanded R&D team